Universal receptor and molecular junction sensors, arrays, and methods for events-based detection and quantitation of small molecules
The universal receptor and molecular junction sensor address the challenges of high costs and complexity in small molecule detection by enabling real-time, sensitive, and versatile detection and quantification of small molecules, suitable for wearable and clinical applications.
Patent Information
- Application Number
- PCT/US2026/027459
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current small molecule detection technologies face challenges such as high costs, operational complexity, and limitations in scalability and reproducibility, hindering broader adoption and advancement in clinical diagnostics and personalized healthcare.
A universal receptor comprising a macrocyclic host configured for noncovalent interactions with small molecules, conjugated to a molecular wire, forms a molecular junction sensor with electrodes to transduce conformational changes into electrical signals for sensitive, event-based detection and quantification.
Enables real-time, single-molecule-level analysis with high sensitivity and versatility, suitable for wearable and clinical applications, overcoming the limitations of existing technologies.
Smart Images

Figure US2026027459_12112026_PF_FP_ABST
Abstract
Description
Atorney Docket No. 22824.002WO-PCTUNIVERSAL RECEPTOR AND MOLECULAR JUNCTION SENSORS, ARRAYS, AND METHODS FOR EVENTS-BASED DETECTION AND QUANTITATION OF SMALL MOLECULESRELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U.S. provisional patent application 63 / 803,456, filed May 9, 2025, titled “UNIVERSAL RECEPTOR AND MOLECULAR JUNCTION SENSOR FOR SINGLE SMALL MOLECULE DETECTION IN AN ELECTRONIC DEVICE,” the entirety of the disclosure of which is hereby incorporated by this reference.SEQUENCE LISTING
[0002] In accordance with 37 C.F.R. § 1.831, the present specification makes reference to a Sequence Listing submitted electronically in the form of an XML file (entitled “228424-002SeqList.xml”, created on May 8, 2026, 6,839 bytes in size). The entire contents of the Sequence Listing are herein incorporated by reference in their entirety, with the intention that, upon publication (including issuance), this incorporated Sequence Listing will be inserted in the published document immediately before the claims.TECHNICAL FIELD
[0003] This development relates to a universal receptor for detecting and quantifying small molecules, such as metabolites, drugs, and hormones, in various biofluids, including sweat, saliva, urine, and blood.BACKGROUND
[0004] The detection of certain types of small molecules is essential for clinical diagnostics, drug monitoring, personalized healthcare, and disease management. By enabling the measurement of small molecules at extremely low concentrations, early diagnosis of conditions that might otherwise remain undetected is possible. Additionally, precise small molecule detection supports personalized medicine by tailoring treatments to an individual's unique metabolic state or pharmacokinetic profile.
[0005] Recent advancements have expanded small molecule testing to home-based and wearable applications. For example, wearable sensors allow continuous glucose monitoring forAtorney Docket No. 22824.002WO-PCTdiabetes management, real-time detection of toxins or pathogens in the environment, and measurement of stress biomarkers such as cortisol in sweat. These sensors integrate advanced materials, electronics, and signal processing to achieve label-free and continuous biomarker analysis from sweat, saliva, or interstitial fluid, offering significant benefits for disease management and personalized healthcare.
[0006] Current detection technologies include LC-MS / MS (Liquid Chromatography-Tandem Mass Spectrometry), immunoassays, and electronic biosensors. LC-MS / MS is widely regarded as the gold standard for small molecule analysis due to its exceptional sensitivity, specificity, and broad analyte detection capabilities. However, its high operational costs, requirement for skilled personnel, and limited suitability for field applications present challenges. Immunoassays, such as ELISA, are simpler and more cost-effective but face issues like batch-to-batch variability and biological matrix interferences. Emerging electronic biosensing technologies, including CMOS-integrated molecular sensors, nanopore platforms, and graphene-based field-effect transistors, offer real-time, label-free detection with high sensitivity. These devices leverage nanoscale engineering and advanced manufacturing techniques to address challenges in diagnostics and environmental monitoring.
[0007] Despite significant progress, current technologies face critical limitations, including high costs, operational complexity, and challenges in scalability and reproducibility. Addressing these shortcomings remains crucial for enabling broader adoption and advancing the field of small molecule detection.SUMMARY
[0008] Aspects of this disclosure relate to a universal receptor comprising a macrocyclic host configured to bind to at least one of metabolites, drugs, hormones, sugars, amino acids, and neurotransmitters through noncovalent interactions, wherein the macrocyclic host is functionalized for conjugation to a molecular wire.
[0009] Certain embodiments may comprise one or more of the following features. The macrocyclic host may further comprise a cavity configured to receive the small molecules and to undergo analyte-dependent structural, conformational, electronic, and / or electrostatic perturbations upon binding. The molecular wire may comprise DNA, RNA, peptide, protein, conductive polymer, or a combination thereof. The macrocyclic host may be configured for conjugation to the molecular wire through an alkyl chain linker. The alkyl chain linker may have a length of 2 to 10 carbons or 2 to 4 carbons. The alkyl chain linker may comprise aAtorney Docket No. 22824.002WO-PCTterminal functional group selected from azide, thiol, carboxylate, aldehyde, alkyne, or amine. The macrocyclic host may further comprise a calixarene core. The calixarene core may comprise an upper rim and a lower rim, the upper rim may be functionalized with at least one substituent group selected from the group consisting of carboxamide, carboxylate, guanidinium, amidinium, phosphate, and sulfate, and the lower rim may be functionalized with at least one substituent group selected from the group consisting of alkyl amine, thiol, carboxylate, alkene, azide, and alkyne. The upper rim may be functionalized with carboxamide. The lower rim may be functionalized with azide-terminated carbon chains. The calixarene core may comprise three, four, five, six, seven, or eight phenyl rings. The universal receptor may further comprise that the calixarene core is a calix[4]arene core. The calixarene core may be functionalized with carboxamide groups on an upper rim of the calixarene core and azide-terminated carbon chains on a lower rim of the calixarene core. The macrocyclic host may comprise a cyclodextrin selected from a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, and substituted cyclodextrins. The cyclodextrin may be mono-azide functionalized for conjugation to the molecular wire at a single anchor point. The macrocyclic host may be configured such that binding of different small molecules produces distinguishable perturbations in a molecular junction sensor.
[0010] Aspects of this disclosure relate to a molecular junction sensor, comprising a universal receptor comprising a macrocyclic host configured to bind small molecules via noncovalent interactions, a molecular wire conjugated to the universal receptor to form a molecular junction with nanostructures or nanoparticles, and a pair of electrodes, wherein the molecular junction is loaded onto the pair of electrodes and is configured to bridge the pair of electrodes to form a conductive pathway, wherein binding events between analytes and the universal receptor cause conformational changes that yield distinct electrical outputs, and wherein the molecular junction sensor is configured to transduce the conformational changes into measurable electrical signals, and wherein the electrical signals are configured to provide time-resolved, event-based detection, identification, and quantification of diverse analytes in biofluids.
[0011] Certain embodiments may comprise one or more of the following features. The pair of electrodes may be spaced by a sub-micrometer gap. The molecular wire may comprise at least one of DNA, RNA, peptide, protein, and conductive polymers. The molecular wire may be DNA, RNA, or a peptide supporting charge transport upon receptor conformational changes. The molecular wire may comprise a DNA molecular wire having an end-to-end length of less than about 5 nm. The DNA molecular wire may have a length of 6 to 15 nucleotides orAtorney Docket No. 22824.002WO-PCTnucleotide pairs. The DNA molecular wire may form at least a portion of the conductive pathway, and the sensor may be configured such that binding of the small molecules to the universal receptor modulates base-mediated hopping, quantum tunneling, or a combination thereof, through the DNA molecular wire. The molecular junction sensor may be configured with single-molecule detection sensitivity. The nanostructures or nanoparticles forming the molecular junction may comprise conductive materials selected from gold nanoparticles, gold nanorods, carbon nanotubes, graphene, and metal-semiconductor hybrids. The molecular junction may be anchored onto the pair of electrodes covalently, electrostatically, or a combination thereof. The universal receptor may allow multiplex detection of multiple analytes in a single assay. The molecular junction sensor may be integrated into a wearable device, a portable device, or a clinical diagnostic platform to enable monitoring of sweat, saliva, urine, blood, or interstitial fluid. The pair of electrodes may be part of a microelectrode array (MEA) comprising a plurality of individually addressable sensing elements. The molecular junction sensor may be configured to provide diagnostic insights for conditions including diabetes, metabolic disorders, kidney dysfunction, dehydration, stress levels, and environmental exposures to toxins or pathogens. The molecular junction sensor may be manufactured using processes that are compatible with scalable, cost-effective mass production. The universal receptor may be conjugated to the molecular wire at a single anchor point. The universal receptor may comprise a mono-azide functionalized cyclodextrin, and the molecular wire may comprise a single-stranded DNA having a single centrally located alkyne-modified base. The single-stranded DNA may comprise a GC-rich sequence configured to facilitate charge transport. The single-stranded DNA may comprise the sequence GGCCGGNGGCCGG, wherein N is an alkyne-modified base (SEQ ID NO: 3). The universal receptor may be conjugated to the molecular wire at a plurality of anchor points. The molecular wire may comprise a multi -stranded nucleic acid and each of the plurality of anchor points may be located on a single strand of the multi-stranded nucleic acid. The universal receptor may comprise a bis-azide functionalized calixarene conjugated to the single strand of the multi -stranded nucleic acid at exactly two anchor points via two adjacent modified bases. The molecular wire may comprise a multi -stranded nucleic acid comprising a first strand and a second strand and the universal receptor may be conjugated to the molecular wire via at least a first anchor point located on the first strand and at least a second anchor point located on the second strand. The sensor may comprise an array of sensing channels and at least one reference channel lacking a receptor or analyte-binding moiety. Output from the at least one reference channel may be usedAtorney Docket No. 22824.002WO-PCTto normalize drift associated with pH, ionic strength, matrix composition, biofouling, lifetime effects, or device-to-device variation. Transient binding events may be characterized by one or more features selected from the group consisting of event amplitude, dwell time, and event rate. A diagnostic output may be generated after accumulation of sufficient event statistics to satisfy a predetermined confidence threshold or time-to-result criterion. Analyte identification or concentration estimation may be performed using a trained classifier or a trained regression model. The trained classifier or trained regression model may comprise one or more of a support vector machine, a kernel classifier, a linear classifier, a tree-based model, a hyperdimensional model, a ridge regression model, or a combination thereof. The molecular junction sensor may be configured for time-resolved, event-based detection of analyte binding events. The sensor may comprise a plurality of sensing channels, a first sensing channel comprising a calixarene-based universal receptor and a second sensing channel comprising a cyclodextrin-based universal receptor. The sensor may comprise a plurality of sensing channels comprising calixarene-based hosts, cyclodextrin-based hosts, or a combination thereof.
[0012] Aspects of this disclosure relate to a method of detecting and quantifying metabolites, drugs, hormones, sugars, amino acids, and / or neurotransmitters, comprising contacting a biofluid sample with a universal receptor or a molecular junction sensor, wherein the universal receptor comprises a macrocyclic host configured to bind small molecules through noncovalent interactions and is functionalized for conjugation to a molecular wire, and wherein the molecular junction sensor comprises the universal receptor, a molecular wire conjugated to the universal receptor to form a molecular junction with nanostructures or nanoparticles, and a pair of electrodes, the molecular junction being configured to bridge the pair of electrodes and to transduce binding-induced conformational changes into measurable electrical signals.
[0013] Certain embodiments may comprise one or more of the following features. The biofluid sample may be selected from the group consisting of sweat, saliva, urine, blood, interstitial fluid, an artificial sweat composition, and an interstitial-fluid-like matrix. The method may detect and quantify at least one molecule selected from the group consisting of glucose, lactate, hydroxybutyrate, uric acid, creatinine, urea, cortisol, dopamine, and serotonin. The method may detect and quantify any combination of glucose, lactate, hydroxybutyrate, uric acid, creatinine, and urea. The method may detect and quantify any combination of glucose, P-hydroxybutyrate, cortisol, lactate, uric acid, creatinine, urea, dopamine, and serotonin.
[0014] The foregoing and other aspects, features, and advantages will be apparent from the DESCRIPTION and DRAWINGS, and from the CLAIMS if any are included.Atorney Docket No. 22824.002WO-PCTBRIEF DESCRIPTION OF THE DRAWINGS
[0015] Implementations will hereinafter be described in conjunction with the appended and / or included DRAWINGS, where like designations denote like elements.
[0016] FIG. l is a representation of a universal receptor-based molecular junction electrical device for biosensing according to some embodiments.
[0017] FIG. 2A is a representation of a chemical structure of calix[4]arene based universal receptor (UR) according to some embodiments.
[0018] FIG. 2B is a representation of a Density Functional Theory (DFT) model of the UR according to some embodiments.
[0019] FIG. 2C is a computer model of the UR-DNA molecular wire conjugate with energy minimization according to some embodiments.
[0020] FIG. 3 is a representation of DFT structures ofUR-small molecule complexes according to some embodiments.
[0021] FIG. 4 is a representation of a synthetic route to the calix[4]arene UR according to some embodiments.
[0022] FIG. 5 is a representation of a general structure of calixarene UR according to some embodiments.
[0023] FIG. 6 is a representation of a chemical process to construct a UR-DNA conjugate according to some embodiments.
[0024] FIG. 7 is a representation of a chemical process to construct a carbon nanotube-DNA junction according to some embodiments.
[0025] FIG. 8 is a representation of a chemical process to construct a gold nanoparticle-DNA junction according to some embodiments.
[0026] FIG. 9 is a representation of a chemical process to load a gold nanoparticle-DNA junction onto the electrodes covalently according to some embodiments.
[0027] FIG. 10 is a representation of a gold nanorod-DNA junction loaded onto the electrodes according to some embodiments.
[0028] FIG. 11 is a representation of 5-azido-l,3-diisopropylbenzimidazolium functionalized gold nanoparticles for forming a gold nanoparticle-DNA junction according to some embodiments.
[0029] FIG. 12 is a representation of computer modeling of the conjugate of UR with a peptide wire containing amino ends according to some embodiments.Atorney Docket No. 22824.002WO-PCT
[0030] FIG. 13 is a representation of computer modeling of the conjugate of UR with a peptide wire containing bicyclo[6.1.0]nonyne (BCN) ends according to some embodiments.
[0031] FIG. 14 is a representation of computer modeling of the conjugate of UR with a peptide wire containing azide ends according to some embodiments.
[0032] FIG. 15 is a representation of a chemical process to construct a peptide-CNT junction according to some embodiments.
[0033] FIG. 16 is a computer model of the mono-triazole modified P-cyclodextrin conjugated to a DNA molecular wire, demonstrating the structural feasibility of the universal receptorwire assembly according to some embodiments.
[0034] FIG. 17 is a representation of Density Functional Theory (DFT) optimized structures of the mono-triazole modified P-cyclodextrin receptor in an isolated state and in complex with cortisol, dopamine, and serotonin, including calculated thermodynamic binding energies (AE), according to some embodiments.
[0035] FIG. 18 is a representation of a chemical process to construct a cyclodextrin-DNA conjugate according to some embodiments.DETAILED DESCRIPTION
[0036] Detailed aspects and applications of the disclosure are described below in the following drawings and detailed description of the technology. Unless specifically noted, it is intended that the words and phrases in the specification and the claims be given their plain, ordinary, and accustomed meaning to those of ordinary skill in the applicable arts.
[0037] In the following description, and by way of explanation, numerous specific details are set forth in order to provide a thorough understanding of the various aspects of the disclosure. It will be understood, however, by those skilled in the relevant arts, that embodiments of the technology disclosed herein may be practiced without these specific details. It should be noted that there are many different and alternative configurations, devices, and technologies to which the disclosed technologies may be applied. The full scope of the technology disclosed herein is not limited to the examples described below.
[0038] The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a step” includes reference to one or more of such steps.
[0039] The word “exemplary,” “example,” or various forms thereof are used herein to mean serving as an example, instance, or illustration. Any aspect or design described herein asAtorney Docket No. 22824.002WO-PCT“exemplary” or as an “example” is not necessarily to be construed as preferred or advantageous over other aspects or designs. Furthermore, examples are provided solely for purposes of clarity and understanding and are not meant to limit or restrict the disclosed subject matter or relevant portions of this disclosure in any manner. It is to be appreciated that a myriad of additional or alternate examples of varying scope could have been presented but have been omitted for purposes of brevity.
[0040] Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, mean “including but not limited to”, and are not intended to (and do not) exclude other components.
[0041] As required, detailed embodiments of the present disclosure are included herein. It is to be understood that the disclosed embodiments are merely exemplary of the invention that may be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limits, but merely as a basis for teaching one skilled in the art to employ the present invention. The specific examples below will enable the disclosure to be better understood. However, they are given merely by way of guidance and do not imply any limitation.
[0042] The present disclosure may be understood more readily by reference to the following detailed description taken in connection with the accompanying figures and examples, which form a part of this disclosure. It is to be understood that this disclosure is not limited to the specific materials, devices, methods, applications, conditions, or parameters described and / or shown herein, and that the terminology used herein is for the purpose of describing particular embodiments by way of example only and is not intended to be limiting of the claimed inventions. The term “plurality”, as used herein, means more than one. When a range of values is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. All ranges are inclusive and combinable.
[0043] More specifically, this disclosure, its aspects and embodiments, are not limited to the specific material types, components, methods, or other examples disclosed herein. Many additional material types, components, methods, and procedures known in the art are contemplated for use with particular implementations from this disclosure. Accordingly, for example, although particular implementations are disclosed, such implementations and implementing components may comprise any components, models, types, materials, versions,Atorney Docket No. 22824.002WO-PCTquantities, and / or the like as is known in the art for such systems and implementing components, consistent with the intended operation.
[0044] The present disclosure relates to a universal receptor (UR) for detecting and quantifying small molecules, such as metabolites, drugs, and hormones, in various biofluids, including interstitial fluid (ISF), sweat, saliva, urine, and blood. As used herein, a “universal receptor” refers to a molecular recognition element configured to bind multiple chemically distinct small molecules through noncovalent interactions and is not limited to any particular molecular scaffold or host-guest architecture. In some embodiments, the universal receptor (UR) is cross-reactive across a class of structurally distinct analytes rather than being limited to a single analyte-specific interaction. These small molecules may be metabolites, drugs, hormones, sugars, amino acids, and / or neurotransmitters, though other small molecules may also be bound and thus detected by the UR. By harnessing specific molecular interactions (e.g., hydrogen bonding and hydrophobic effects), the UR enables broad-spectrum analyte detection suitable for numerous applications in wearable health monitoring, portable home use, and clinical diagnostics, as well as personalized medicine. In certain implementations, the UR enables detection of glucose, lactate, hydroxybutyrate, uric acid, creatinine, and urea. In some embodiments, the UR enables detection of glucose, P-hydroxybutyrate, cortisol, lactate, uric acid, creatinine, urea, dopamine, and serotonin. Thus, the UR described herein enables the detection of glucose, lactate, hydroxybutyrate (such as P-hydroxybutyrate), cortisol, uric acid, creatinine, urea, dopamine, serotonin, and any combination thereof. The molecular junction sensor can therefore be configured to monitor conditions including diabetes, metabolic disorders, kidney dysfunction, dehydration, neurological or neurodegenerative conditions; stress levels; and environmental exposures to toxins or pathogens. In certain implementations, the molecular junction sensor can provide diagnostic insights into a variety of conditions such as diabetes, metabolic disorders, kidney dysfunction, dehydration, and neurological or neurodegenerative conditions. Integrating the UR into electronic or optical sensing platforms allows for real-time, single-molecule-level analysis, significantly improving the sensitivity and versatility of conventional testing methods in both clinical and consumer settings.
[0045] In some embodiments, the UR comprises a macrocyclic host configured to bind small molecules through noncovalent interactions and functionalized for conjugation to a molecular wire. The macrocyclic host comprises a cavity or other molecular recognition environment configured to receive chemically distinct small molecules and to undergo analyte-dependent structural, conformational, electronic, and / or electrostatic perturbations upon binding. In someAtorney Docket No. 22824.002WO-PCTembodiments, the UR is configured to bind a plurality of chemically distinct small molecules, including metabolites, drugs, hormones, sugars, amino acids, neurotransmitters, or combinations thereof.
[0046] In some embodiments, the UR comprises a calixarene core functionalized with carboxamide groups and azide-terminated carbon chains. Calixarene is a macrocycle or cyclic oligomer based on methylene-linked phenols and is characterized by a three-dimensional basket or bucket shape. In other words, the shape of a calixarene comprises a wide upper rim, a narrow lower rim, and a central annulus. In some aspects, the calixarene core is functionalized with carboxamide groups on the upper rim and azide-terminated carbon chains on the lower rim. In some embodiments, as shown in FIG. 5, the calixarene core may have three, four, five, six, seven, or eight phenyl rings and the core may be functionalized with various upper-rim substituents, e.g., carboxamide, carboxylate, guanidinium, amidinium, phosphate, sulfate, or other functional groups, to expand the range of possible hydrogen bonding. The lower rim can be functionalized with alkyl amine, thiol, carboxylate, alkene, azide, or alkyne groups, enabling broad chemical strategies for anchoring to molecular wires, such as DNA, RNA, peptides, proteins, or conductive polymers. In some embodiments, the UR is attached to the molecular wire through an alkyl chain linker having from 2 to 10 carbon atoms, such as from 2 to 4 carbon atoms. In some embodiments, the alkyl chain linker comprises a terminal functional group configured to facilitate attachment of the molecular wire to the UR, such as an azide, thiol, carboxylate, aldehyde, alkyne, amine, or other reactive functionality. As used herein, DNA and RNA include their modifications and analogues, such as locked nucleic acid (LNA) and peptide nucleic acid (PNA). In some embodiments, the molecular wire comprises a hybrid or composite structure, including combinations of nucleic acids, peptides, proteins, polymers, or aromatic molecular segments. In some embodiments, DNA, RNA, or peptide molecular wires support charge transport and transduce receptor-induced structural, conformational, electronic, and / or electrostatic perturbations into measurable electrical outputs.
[0047] In some embodiments, the UR comprises a macrocyclic host other than a calixarene core, such as a cyclodextrin core. The cyclodextrin core may be selected from a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, or substituted cyclodextrins functionalized to permit conjugation to DNA, RNA, peptides, proteins, conductive polymers, or nanostructures. Cyclodextrin-based hosts may be used alone, in mixtures with calixarene-based hosts, or in different channels of a multiplexed array on a chip. For example, a first sensing channel may comprise a calixarene-based UR and a second sensing channel may comprise a cyclodextrin-Atorney Docket No. 22824.002WO-PCTbased UR. In some embodiments, the macrocyclic host is functionalized for conjugation to a molecular wire comprising DNA, RNA, peptide, protein, conductive polymer, or a combination thereof.
[0048] In some embodiments, a cyclodextrin-DNA conjugate is formed by reacting a functionalized cyclodextrin, such as mono-6-azido-6-deoxy-P-cyclodextrin, with a DNA containing an alkyne-modified nucleotide, such as 2’-deoxy-5-ethynyluridine, to produce a receptor-wire conjugate configured for incorporation into a molecular junction sensor (FIG.18).
[0049] In certain embodiments, the UR comprises a calix[4]arene core functionalized with carboxamide groups on the upper rim for hydrogen bonding and azide-terminated carbon chains on the lower rim for conjugation (FIG. 2A). DFT modeling (FIG. 2B) indicates the UR has a cup-shaped structure with a hydrophobic cavity formed by the four phenyl groups. In some embodiments, Density Functional Theory (DFT) modeling of the calix[4]arene complexes is performed using a B3LYP functional selected to characterize hydrogen-bonding networks and electrostatic interactions associated with target inclusion at the carboxamide-functionalized upper rim. The UR can be conjugated to a DNA wire via an azide-alkyne click reaction, such as through the structure shown in FIG. 2C, to produce a universal sensor component. FIG. 3 shows the DFT structures of the complexes formed by UR interacting with small molecules in some embodiments. Each complexing alters the UR’s conformation differently (FIG. 3), which may perturb DNA base stacking and modulate the DNA wire’s electrical resistance to various degrees. This offers a unique way to identify individual molecules as well as providing the potential for anomer discrimination. For example, a-glucose forms a four-hydrogen bonding (HB) complex with the UR, whereas 0-glucose forms a three-HB complex (not shown). Whereas glucose, lactate, hydroxybutyrate, uric acid, and creatinine molecules form a 1:1 complex with the UR, urea forms a 3:1 complex. Thus, the UR can also distinguish between different molecules by their binding stoichiometry and resulting receptor conformation.
[0050] In some embodiments, a functionalized cyclodextrin core binds diverse analytes, including steroid hormones such as cortisol and aromatic or monoamine neurotransmitters such as dopamine and serotonin. Molecular modeling, including Density Functional Theory (DFT) in some embodiments, indicates that cyclodextrin-based receptors can efficiently capture these structurally distinct targets in aqueous environments. For bulky steroid hormones like cortisol, binding may be driven in substantial part by the hydrophobic effect, wherein the fused ringAtorney Docket No. 22824.002WO-PCTsystem inserts into the hydrophobic cyclodextrin cavity to displace high-energy water molecules. Similarly, for monoamine neurotransmitters, favorable van der Waals interactions anchor the aromatic rings within the cavity, while the explicitly solvated, protonated ammonium tails protrude from the cavity rim to maintain a stabilizing hydrogen-bond network with the bulk aqueous phase. This may mitigate artificial desolvation penalties and yield favorable and distinguishable thermodynamic binding energies (AE) based on the specific size, shape, and hydrophobicity of the analyte.
[0051] The present disclosure also provides a single-molecule sensing electronic device based on the UR. As shown in FIG. 1, in some embodiments, the UR 101 is conjugated with a DNA molecular wire 102, which bridges two nanostructures 103 to form a molecular junction. In some embodiments, the UR is conjugated to the molecular wire at a single anchor point. In some embodiments, the macrocyclic host is configured for conjugation to the molecular wire through an alkyl chain linker. The molecular junction may be loaded onto two electrodes 104 separated by a nanometer-scale or sub-micrometer gap, creating an electrical circuit. When a bias is applied, molecular interactions can be measured in real-time. The pair of electrodes may comprise conductive materials, which may be selected from gold, platinum, palladium, copper, and other metals, as well as their alloys. For example, the pair of electrodes may comprise or incorporate conductive elements selected from gold nanoparticles, gold nanorods, carbon nanotubes, graphene, metal-semiconductor hybrids, or combinations thereof. In some embodiments, the conjugate forms a nanojunction with conductive materials selected from gold nanoparticles, gold nanorods, carbon nanotubes, graphene, or metal-semiconductor hybrids. In some embodiments, the molecular junction is covalently anchored onto the pair of electrodes through click chemistry. As used herein, click chemistry includes, but is not limited to azidealkyne cycloaddition, Staudinger ligation, aldehyde-oxyamine, carboxylate-amine, or thiolgold interactions. In some embodiments, the molecular junction is anchored onto the pair of electrodes electrostatically, such as via ionic interactions or oppositely charged surface functionalities, or through a combination of covalent and electrostatic interactions.
[0052] In some embodiments, the UR is integrated with a short DNA molecular wire to form a UR-molecular wire conjugate. The DNA molecular wire may have an end-to-end length of less than about 5 nm, such as from about 2 nm to about 5 nm or from about 3 nm to about 5 nm. In some embodiments, the DNA molecular wire has a length of 6 to 15 nucleotides or nucleotide pairs. The DNA molecular wire may include one or more internally positioned modified bases covalently coupled to the UR. In some embodiments, the DNA molecular wireAtorney Docket No. 22824.002WO-PCTis configured to support base-mediated hopping, tunneling across one or more molecular junctions, or a combination thereof, such that binding of a small molecule to the UR alters base stacking, 7t-orbital overlap, local torsion, or conformation of the DNA molecular wire and thereby modulates electron transport through the DNA molecular wire. In some embodiments, a double-stranded nucleic acid wire has an end-to-end length estimated at about 0.34 nm per base pair; for example, a 13-base-pair wire may have a length of about 4.4 nm.
[0053] In some embodiments, the molecular junction sensor is configured as a molecular junction conduction sensor rather than a field-effect transistor sensor. In such embodiments, the DNA molecular wire forms at least a portion of the active conductive pathway between first and second conductive junction elements, and the measured current or conductance events arise from direct modulation of hopping and / or tunneling transport through the DNA molecular wire. In some embodiments, the sensor is configured to operate in buffer, biofluid, artificial sweat, interstitial-fluid-like matrix, or physiological ionic- strength samples in which long-range electrostatic field-effect gating is attenuated while receptor-induced perturbations of the molecular wire remain detectable.
[0054] In certain embodiments, the molecular junction is a self-aligned SWCNT-DNA(UR)- SWCNT junction, optionally deposited onto lithographically defined electrode pairs or a microelectrode array (MEA) to form a plurality of individually addressable sensing elements. One or more array elements may omit the receptor or other analyte-binding moiety and serve as reference junctions for normalization of matrix- or device-driven drift. In some embodiments, signals from the reference junctions are used to normalize drift associated with pH, ionic strength, matrix composition, biofouling, or device-to-device variation.
[0055] In some embodiments, the molecular wire is a peptide composed of the WWP motifs, containing a single-point modification for conjugation with UR. Tryptophan (W) indole side chains provide 7t-orbital overlap, facilitating hopping-based electron transport. Proline residues in the WWP motif likely induce periodic turns, shortening the effective tunneling distance between electrodes. Molecular dynamics simulations of similar peptides reveal that P-turns reduce the end-to-end distance by 2-3 A compared to linear conformations, enhancing the electronic coupling between aromatic residues.
[0056] In some embodiments, the peptide molecular wire is a sequence of NH2-GWWPWWPWWPF*WPWWPWWM-NH2(SEQ ID NO. 1, wherein F* = 4-Azidophenyl alanine and M = L-2,3-Diaminopropionic acid), which forms a conjugate (1202) with UR 1201 through one carbon-chain linker (FIG. 12).Atorney Docket No. 22824.002WO-PCT
[0057] In some embodiments, the ends of peptide 1202 are modified with bicyclo[6.1.0]nonyne (BCN), which forms a conjugate (1301) with UR 1201 through a click reaction (FIG. 13).
[0058] In some embodiments, the amino ends of peptide 1202 are converted to azides, which form a conjugate (1401) with UR 1201 through a carbon-chain linker (FIG. 14).
[0059] A sample containing various small molecules 105 may be introduced. In some embodiments, the molecular junction sensor is configured to transduce binding-induced structural, conformational, electronic, and / or electrostatic perturbations between the UR and the small molecules into measurable electrical signals. In some embodiments, such perturbations include conformational changes. As used herein, “electrical signals” include, without limitation, changes in current, conductance, resistance, impedance, tunneling probability, noise characteristics, or combinations thereof.
[0060] The binding events between analytes and the UR cause conformational changes of the molecular wire, which yield distinct electrical outputs. The small molecules interact with the UR noncovalently and dissociate stochastically, altering the UR’s conformation and causing current fluctuations 106. Because the UR has a flexible structure and a functionalized cavity, different analytes produce distinct binding signatures based on, for example, size, shape, function, and hydrophobicity. In some embodiments, different analytes produce distinguishable electrical signatures based on binding stoichiometry, receptor occupancy, or cooperative interactions. For example, the transient inclusion of targets into the calixarene or cyclodextrin cavity perturbs the conjugated molecular wire, yielding target-specific event features for algorithmic identification.
[0061] In some embodiments, complexation of target analytes induces conformational changes within the UR and / or linker region, and such changes serve as a transduction mechanism by modulating charge transport through the molecular wire. For example, the inclusion of dopamine into the mono-triazole modified P-cyclodextrin (P-CDTrZ) cavity is thermodynamically favorable in some embodiments, yielding a binding energy (AE) of approximately -24 kcal / mol (FIG. 17). As detailed in Table 1, this strong noncovalent binding event physically distorts the lower rim of the macrocycle. Notably, the N18-C16-C15-O17 torsion angle, which anchors the triazole linker to the receptor core, shifts from -69.17° in the isolated state to -79.18° upon dopamine complexation. This -10° torsional rotation acts as a mechanicallever at the base of the conjugated molecular wire. Because the wire spans a nanometer-scale electrode gap, this localized torsional strain significantly displaces the wire’sAttorney Docket No. 22824.002WO-PCTTable 1. Target-Specific Conformational Changes of the Cyclodextrin Receptor z <> in co _ Demonstrated by Torsion Angle Shifts _ _1n P-CDTrZ+ P-CDTrZ+ incTorsion A 1ngle (°)* P-CDTrZP-CDTrZ+ dopamine Serotonin n cor (protonated and (protonated and Ulen tisolhydrated) hydrated) 1Af - Cf - Ci - O O J{ -69.17 -78.54 -79.18 -76.50 0% - C% - cl - O7-69.05 -70.44 -70.63 -68.18 Of - C% - Cl - Ol 61.67 66.22 71.36 71.65 Of - Cl - Cl - Ol 83.57 87.49 86.86 87.5568.62 65.30 66.53 67.06 r)8 _ r6 _ rS _ z)7Uf>L6L6Uf> 55.25 58.96 58.58 59.000% - Cl - Cl - Ol 165.10 167.60 175.57 173.36 * Each atom defining a torsion angle is denoted as A" where "A" represents the atomic element, "r" indicates the specific sugar ring number (1 through 7), and "n" indicates the standard atom position within that sugar ring, as labeled in the accompanying structural diagram below.OHStructure of mono-triazole modified p-CD (p-CDTrZ) utilized as the universal receptor in DFT modelingconformation, measurably perturbing the overlapping 7t-orbitals and modulating the current flowing across the molecular junction. Furthermore, even in instances where distinct analytes exhibit nearly identical thermodynamic binding energies, their unique steric profiles imposeAtorney Docket No. 22824.002WO-PCTvarying activation energy barriers for cavity entry and exit; this structural divergence can cause the analytes to produce distinguishable kinetic rates (konand koff) and junction resistance changes, which may be resolved as differing event rates, dwell times, and current amplitudes.
[0062] In some embodiments where the DNA molecular wire is less than about 5 nm long, even small analyte-induced changes in receptor orientation, linker torsion, or base stacking can produce measurable changes in hopping and / or tunneling current. In some embodiments, each binding and dissociation event produces a time-resolved current feature whose amplitude, polarity, rise time, dwell time, recovery time, spectral content, or event-to-event variability reflects the identity, concentration, occupancy state, or binding mode of the analyte.
[0063] Thus, the electrical signals are configured to provide real-time detection, identification, and / or quantification of diverse analytes in biofluids. In some embodiments, the molecular junction sensor is configured for time-resolved, event-based detection of analyte binding events rather than continuous equilibrium readout. In some embodiments, the sample contains multiple analytes simultaneously, and the resulting electrical outputs comprise overlapping or mixed event populations that are resolved using the disclosed analysis framework.
[0064] In some embodiments, stochastic binding and dissociation events are segmented or detected algorithmically, optionally using thresholding, Hidden Markov Models, or other event-detection methods, to extract event amplitude, dwell time, and event-rate features. The extracted event features may be processed in a feature-based analysis pipeline comprising normalization, filtering, classifier and / or regression modeling, mixture deconvolution, and, in some embodiments, predictive validation across devices or chips, such that diagnostic output reflects the aggregate event distribution rather than any single event.
[0065] In some embodiments, analyte identification and / or concentration estimation is performed using a trained classifier and / or a trained regression model. Example models include support vector machines, linear classifiers, kernel classifiers, tree-based models, hyperdimensional models, ridge regression, and combinations thereof. In some embodiments, there is no limitation to any particular algorithm family. In some embodiments, analyte identification or quantification is performed without machine learning, using rule-based classification, thresholding, lookup tables, or deterministic models.
[0066] In some embodiments, time-to-result is defined as the number of events or measurement duration required to reach a selected confidence threshold for analyte identity and / or concentration. Under non-saturating conditions, the total event count rate may increase withAtorney Docket No. 22824.002WO-PCTthe number of active sensing elements and analyte concentration, thereby reducing time-to-result.
[0067] Integrating the UR with a DNA or peptide scaffold and linking it to nanostructures or nanoparticles (e.g., carbon nanotubes, gold nanoparticles) achieves various beneficial characteristics in the resulting single-molecule junction sensor. For example, the singlemolecule junction sensor has high sensitivity, allowing for detection at a single molecule resolution. In addition, the single-molecule junction sensor can be configured with multiplexing capability, potentially tracking multiple analytes simultaneously. Thus, the UR may allow multiplex detection of multiple analytes in a single assay. As another example, the single-molecule junction sensor has good scalability, making it amenable to the industrial manufacturing process. In some embodiments, the molecular junction sensor, and in particular the sensor chips, are manufactured using processes that are compatible with scalable, cost-effective mass production. The described single-molecule sensor is thus set to revolutionize diagnostics by consolidating the detection of multiple biomarkers into a single test. Applications include sweat-based wearable platforms for monitoring glucose, lactate, or electrolytes; point-of-care diagnostics for saliva, blood, or urine; and environmental toxin or pathogen detection. The molecular junction sensor may be integrated into a wearable device, a portable device, or a clinical diagnostic platform to enable real-time monitoring of biomarkers in sweat, saliva, urine, blood, interstitial fluid, artificial sweat compositions, or interstitial-fluid-like matrices.
[0068] In some embodiments, the present disclosure relates to a method to synthesize the UR, such as the process depicted in FIG. 4. The method to synthesize a UR may include any of the following processes. Formylation involves calix[4]arene (401) that is reacted with HMTA under microwave radiation to give p-formylcalix[4]arene (402). Carbamoylation involves treating 402 with hydroxylamine in the presence of cesium carbonate yielding p-carbamoylcalix[4]arene (403). Azido Alkylation involves the selective alkylation of calix[4]arene 403 with l-azido-2-bromoethane in the presence of potassium carbonate, which forms the desired UR product 404.
[0069] In some embodiments, the present disclosure provides a method to conjugate the UR to DNA, wherein the UR comprises a bis-azide functionalized calixarene. In some implementations, the method comprises reacting a single-stranded DNA (ssDNA) containing consecutive 5-ethynyl-2'-deoxyuridine and 7-ethynyl-7-deazadeoxy-adenosine in its sequence (601) with a bis-azide-functionalized UR in the presence of Q1SO4 and sodium ascorbate. AsAtorney Docket No. 22824.002WO-PCTshown in FIG. 6, this produces a UR conjugate anchored to two adjacent DNA bases at two anchor points. The product is purified by HPLC and characterized by MALDI-MASS and FTIR. The UR-ssDNA conjugate hybridizes with its complementary strand to form a UR@DNA conjugate (602). The DNA is terminally functionalized with amino groups for coupling to nanostructures.
[0070] In some embodiments, the UR is conjugated to the molecular wire via a plurality of anchor points distributed across one or more strands of a multi-stranded wire, such as a doublestranded DNA or RNA molecular wire. In some embodiments, a multi -stranded UR-wire conjugate is formed by reacting a bis-azide functionalized UR with two adjacent alkyne-modified bases located on the same strand of a multi -stranded nucleic acid, thereby providing a multi-stranded molecular wire in which both anchor points are located on a single strand. In other embodiments, an inter-strand conjugate is formed by reacting a bis-azide functionalized UR with a first alkyne-modified base located on a first strand and a second alkyne-modified base located on a second strand of the multi -stranded nucleic acid. This inter-strand bridging architecture can be configured to impose distinct mechanical constraints on the molecular wire, thereby allowing varied transduction profiles upon analyte binding.
[0071] In some embodiments, one or more sensing channels comprise a target-specific binder, including peptide-based, aptamer-based, or antibody-based binders, either instead of or in combination with a UR. Arrays may therefore include a combination of cross-reactive universal -receptor channels and target-specific control channels.
[0072] The present disclosure also provides a method to create a CNT- UR@DNA-CNT junction as a single molecular transducer in some embodiments. As described in FIG. 7, carboxylic acids at the end of DNA-wrapped carbon nanotubes (701) are activated to form NHS esters (702) by reacting with NHS in the presence of EDC under acidic conditions. The NHS esters react with amino-terminated UR@DNA (602) in a PBS buffer pH 7.5 - 8.0, resulting in a CNT- UR@DNA-CNT junction (703). The resultant junction is loaded onto the metal electrodes coated with cysteamine following a prior-art protocol or other suitable layers to form the final device.
[0073] In some embodiments, the present disclosure provides a method to create a gold nanoparticle (GNP) based molecular junction: GNP-UR@DNA-GNP. As shown in FIG. 8, GNPs are coated with a mixed monolayer of 3 -mercaptopropionic acid and 2-(4-azidophenyl)ethane-l -thiol (801). UR@DNA (602) is derivatized with bicyclo[6.1.0]nonyne (BCN) (802). Copper-free click chemistry between the azide-bearing GNPs (801) and BCN-Atorney Docket No. 22824.002WO-PCTmodified UR@DNA (802) yields GNP- UR@DNA-GNP (803). The junction can be mounted onto BCN-coated metal electrodes (FIG. 9).
[0074] In some embodiments, the present disclosure provides a method to create a gold nanorod (GNR, 1001) molecular junction: GNR-UR@DNA-GNR. As shown in FIG. 10, GNR is functionalized with multiple phenyl azides by forming a mixed monolayer composed of 3-Mercaptopropionic acid and 2-(4-azidophenyl)ethane-l -thiol on its surface to create a molecular junction with 803, which is loaded onto the electrodes in a similar way as described in the paragraph above. In some embodiments, the phenyl azide in the gold nanoparticles is replaced with N-heterocyclic carbene 5-azido-l,3-diisopropylbenzimidazolium to form a molecular junction 1101 loaded onto the electrodes in a similar way as described in the paragraph above (FIG. 11).
[0075] In some embodiments, the present disclosure provides a method to prepare a peptide CNT junction through a traceless Staudinger Ligation. As shown in FIG. 15, the carboxylic ends of a DNA-wrapped CNT (703) are converted to phosphinoesters (1501), then reacting with Peptide 1401 to form a CNT-UR@Peptide-CNT junction (1502). The junction can be loaded on the metal electrodes coated with cysteamine.
[0076] The present disclosure also relates to a method to synthesize a UR comprising a cyclodextrin core, and the present disclosure provides a method to conjugate the cyclodextrin to a molecular wire to form a single molecular transducer. As shown in FIG. 18, mono-6-azido-6-deoxy-P-cyclodextrin (1801) is reacted with a single-stranded DNA wire containing a single alkyne-modified base, such as a centrally located 5-ethynyl-2’-deoxyuridine (U’) (1802), to produce a UR- wire conjugate (1803) anchored at a single point. In certain implementations, the DNA wire comprises a highly conductive, GC-rich sequence, such as GGCCGGU’GGCCGG (SEQ ID NO: 3), to facilitate rapid charge transport via hole-hopping mechanisms. The resulting conjugate may adopt the structural arrangement illustrated in FIG.16, in which the macrocyclic cavity remains oriented for noncovalent inclusion of target analytes.
[0077] The present disclosure enables detecting and quantifying small molecules, such as metabolites, drugs, hormones, and neurotransmitters, in various biofluids, including sweat, saliva, urine, interstitial fluid, and blood. The UR harnesses specific molecular interactions (e.g., hydrogen bonding and hydrophobic effects) to enable broad-spectrum analyte detection suitable for numerous applications in wearable health monitoring, diagnostics, and personalized medicine. The molecular junction sensor can therefore provide diagnostic insightsAtorney Docket No. 22824.002WO-PCTfor conditions including diabetes, metabolic disorders, kidney dysfunction, dehydration, stress, and provide insights into exposure to toxins or pathogens. Integrating the receptor into electronic or optical sensing platforms allows for real-time, single-molecule-level analysis, significantly improving the sensitivity and versatility of conventional testing methods in both clinical and consumer-based settings.
[0078] In some embodiments, a method of detecting and quantifying metabolites, drugs, hormones, sugars, amino acids, neurotransmitters, or other small molecules comprises providing a biofluid sample and contacting the biofluid sample with a UR or a molecular junction sensor as disclosed herein. In some embodiments, the UR comprises a macrocyclic host configured to bind small molecules through noncovalent interactions and functionalized for conjugation to a molecular wire. In some embodiments, the molecular junction sensor comprises the UR, a molecular wire conjugated to the UR to form a molecular junction with nanostructures or nanoparticles, and a pair of electrodes, wherein the molecular junction bridges the pair of electrodes and transduces binding-induced conformational changes into measurable electrical signals. In some embodiments, the UR is contacted with the biofluid sample prior to, during, or independent of incorporation into the molecular junction sensor.
[0079] In some embodiments, the biofluid sample is selected from sweat, saliva, urine, blood, interstitial fluid, an artificial sweat composition, or an interstitial-fluid-like matrix. In some embodiments, the method detects and quantifies at least one, or any combination, of glucose, lactate, hydroxybutyrate, uric acid, creatinine, and urea. In some embodiments, the method detects and quantifies at least one, or any combination, of glucose, P-hydroxybutyrate, cortisol, lactate, uric acid, creatinine, urea, dopamine, and serotonin.
[0080] In some embodiments, feasibility testing and benchmarking are performed in controlled buffer and in physiologically relevant model matrices including commercially available artificial sweat and commercially sourced or composition-matched ISF-like matrices. Such testing may include defined interferents, pH and ionic- strength variation, biofouling and lifetime stress, and later-stage expansion to de-identified clinical samples.
[0081] Many additional implementations are possible. Further implementations are within the CLAIMS.
[0082] It will be understood that implementations of the UR and molecular junction sensor include but are not limited to the specific components disclosed herein, as virtually any components consistent with the intended operation of various molecular junction sensors may be utilized. Accordingly, for example, it should be understood that, while the drawings andAtorney Docket No. 22824.002WO-PCTaccompanying text show and describe particular molecular junction sensor implementations, any such implementation may comprise any shape, size, style, type, model, version, class, grade, measurement, concentration, material, weight, quantity, and / or the like consistent with the intended operation of molecular junction sensors.
[0083] The concepts disclosed herein are not limited to the specific UR or molecular junction sensors shown herein. For example, it is specifically contemplated that the components included in particular molecular junction sensors may be formed of any of many different types of materials or combinations that can readily be formed into shaped objects and that are consistent with the intended operation of molecular junction sensors. For example, the components may be formed of: rubbers (synthetic and / or natural) and / or other like materials; glasses (such as fiberglass), carbon-fiber, aramid-fiber, any combination therefore, and / or other like materials; elastomers and / or other like materials; polymers such as thermoplastics (such as ABS, fluoropolymers, polyacetal, polyamide, polycarbonate, polyethylene, poly sulfone, and / or the like, thermosets (such as epoxy, phenolic resin, polyimide, polyurethane, and / or the like), and / or other like materials; plastics and / or other like materials; composites and / or other like materials; metals, such as zinc, magnesium, titanium, copper, iron, steel, carbon steel, alloy steel, tool steel, stainless steel, spring steel, aluminum, and / or other like materials; and / or any combination of the foregoing.
[0084] Furthermore, UR and molecular junction sensors may be manufactured separately and then assembled together, or any or all of the components may be manufactured simultaneously and integrally joined with one another. Manufacture of these components separately or simultaneously, as understood by those of ordinary skill in the art, may involve 3-D printing, extrusion, pultrusion, vacuum forming, injection molding, blow molding, resin transfer molding, casting, forging, cold rolling, milling, drilling, reaming, turning, grinding, stamping, cutting, bending, welding, soldering, hardening, riveting, punching, plating, and / or the like. If any of the components are manufactured separately, they may then be coupled or removably coupled with one another in any manner, such as with adhesive, a weld, a fastener, any combination thereof, and / or the like for example, depending on, among other considerations, the particular material(s) forming the components.
[0085] In places where the description above refers to particular molecular junction sensor implementations, it should be readily apparent that a number of modifications may be made without departing from the spirit thereof and that these implementations may be applied toAttorney Docket No. 22824.002WO-PCTother implementations disclosed or undisclosed. The presently disclosed molecular junction sensors are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims
Atorney Docket No. 22824.002WO-PCTCLAIMSWe claim:
1. A universal receptor comprising a macrocyclic host configured to bind to at least one of metabolites, drugs, hormones, sugars, amino acids, and neurotransmitters through noncovalent interactions, wherein the macrocyclic host is functionalized for conjugation to a molecular wire.
2. The universal receptor of claim 1, wherein the macrocyclic host comprises a cavity configured to receive the small molecules and to undergo analyte-dependent structural, conformational, electronic, and / or electrostatic perturbations upon binding.
3. The universal receptor of claim 1, wherein the molecular wire comprises DNA, RNA, peptide, protein, conductive polymer, or a combination thereof.
4. The universal receptor of claim 1, wherein the macrocyclic host is configured for conjugation to the molecular wire through an alkyl chain linker.
5. The universal receptor of claim 4, wherein the alkyl chain linker has a length of 2 to 10 carbons or 2 to 4 carbons.
6. The universal receptor of claim 4, wherein the alkyl chain linker comprises a terminal functional group selected from azide, thiol, carboxylate, aldehyde, alkyne, or amine.
7. The universal receptor of any one of claims 1-6, wherein the macrocyclic host comprises a calixarene core.
8. The universal receptor of claim 7, wherein:the calixarene core comprises an upper rim and a lower rim;the upper rim is functionalized with at least one substituent group selected from the group consisting of: carboxamide, carboxylate, guanidinium, amidinium, phosphate, and sulfate; andthe lower rim is functionalized with at least one substituent group selected from the group consisting of: alkyl amine, thiol, carboxylate, alkene, azide, and alkyne.Atorney Docket No. 22824.002WO-PCT9. The universal receptor of claim 8, wherein the upper rim is functionalized with carboxamide.
10. The universal receptor of claim 8, wherein the lower rim is functionalized with azide-terminated carbon chains.
11. The universal receptor of claim 7, wherein the calixarene core comprises three, four, five, six, seven, or eight phenyl rings.
12. The universal receptor of claim 7, wherein the calixarene core is a calix[4]arene core.
13. The universal receptor of claim 7, wherein the calixarene core is functionalized with carboxamide groups on an upper rim of the calixarene core and azide-terminated carbon chains on a lower rim of the calixarene core.
14. The universal receptor of any one of claims 1-6, wherein the macrocyclic host comprises a cyclodextrin selected from a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, and substituted cyclodextrins.
15. The universal receptor of claim 14, wherein the cyclodextrin is mono-azide functionalized for conjugation to the molecular wire at a single anchor point.
16. The universal receptor of any one of claims 1-6, wherein the macrocyclic host is configured such that binding of different small molecules produces distinguishable perturbations in a molecular junction sensor.
17. A molecular junction sensor, comprising:a universal receptor comprising a macrocyclic host configured to bind small molecules via noncovalent interactions;a molecular wire conjugated to the universal receptor to form a molecular junction with nanostructures or nanoparticles; andAtorney Docket No. 22824.002WO-PCTa pair of electrodes, wherein the molecular junction is loaded onto the pair of electrodes and is configured to bridge the pair of electrodes to form a conductive pathway;wherein binding events between analytes and the universal receptor cause conformational changes that yield distinct electrical outputs; andwherein the molecular junction sensor is configured to transduce the conformational changes into measurable electrical signals, and wherein the electrical signals are configured to provide time-resolved, event-based detection, identification, and quantification of diverse analytes in biofluids.
18. The molecular junction sensor of claim 17, wherein the pair of electrodes are spaced by a sub-micrometer gap.
19. The molecular junction sensor of claim 17 or 18, wherein the molecular wire comprises at least one of DNA, RNA, peptide, protein, and conductive polymers.
20. The molecular junction sensor of claim 19, wherein the molecular wire is DNA, RNA, or a peptide supporting charge transport upon receptor conformational changes.
21. The molecular junction sensor of claim 19, wherein the molecular wire comprises a DNA molecular wire having an end-to-end length of less than about 5 nm.
22. The molecular junction sensor of claim 21, wherein the DNA molecular wire has a length of 6 to 15 nucleotides or nucleotide pairs.
23. The molecular junction sensor of claim 21 or 22, wherein the DNA molecular wire forms at least a portion of the conductive pathway and wherein the sensor is configured such that binding of the small molecules to the universal receptor modulates base-mediated hopping, quantum tunneling, or a combination thereof, through the DNA molecular wire.
24. The molecular junction sensor of any one of claims 17-23, wherein the molecular junction sensor is configured with single-molecule detection sensitivity.Atorney Docket No. 22824.002WO-PCT25. The molecular junction sensor of any one of claims 17-24, wherein the nanostructures or nanoparticles forming the molecular junction comprise conductive materials selected from gold nanoparticles, gold nanorods, carbon nanotubes, graphene, and metal-semiconductor hybrids.
26. The molecular junction sensor of any one of claims 17-25, wherein the molecular junction is anchored onto the pair of electrodes covalently, electrostatically, or a combination thereof.
27. The molecular junction sensor of any one of claims 17-26, wherein the universal receptor allows multiplex detection of multiple analytes in a single assay.
28. The molecular junction sensor of any one of claims 17-27, wherein the molecular junction sensor is integrated into a wearable device, a portable device, or a clinical diagnostic platform to enable monitoring of sweat, saliva, urine, blood, or interstitial fluid.
29. The molecular junction sensor of any one of claims 17-28, wherein the pair of electrodes is part of a microelectrode array (MEA) comprising a plurality of individually addressable sensing elements.
30. The molecular junction sensor of any one of claims 17-29, wherein the molecular junction sensor is configured to provide diagnostic insights for conditions including diabetes, metabolic disorders, kidney dysfunction, dehydration, stress levels, and environmental exposures to toxins or pathogens.
31. The molecular junction sensor of any one of claims 17-30, wherein the molecular junction sensor is manufactured using processes that are compatible with scalable, cost-effective mass production.
32. The molecular junction sensor of any one of claims 17-31, wherein the universal receptor is conjugated to the molecular wire at a single anchor point.Atorney Docket No. 22824.002WO-PCT33. The molecular junction sensor of claim 32, wherein the universal receptor comprises a mono-azide functionalized cyclodextrin, and the molecular wire comprises a single-stranded DNA having a single centrally located alkyne-modified base.
34. The molecular junction sensor of claim 33, wherein the single-stranded DNA comprises a GC-rich sequence configured to facilitate charge transport.
35. The molecular junction sensor of claim 34, wherein the single-stranded DNA comprises the sequence GGCCGGNGGCCGG, wherein N is an alkyne-modified base (SEQ ID NO: 3).
36. The molecular junction sensor of any one of claims 17-31, wherein the universal receptor is conjugated to the molecular wire at a plurality of anchor points.
37. The molecular junction sensor of claim 36, wherein the molecular wire comprises a multi-stranded nucleic acid and wherein each of the plurality of anchor points is located on a single strand of the multi -stranded nucleic acid.
38. The molecular junction sensor of claim 37, wherein the universal receptor comprises a bis-azide functionalized calixarene conjugated to the single strand of the multi -stranded nucleic acid at exactly two anchor points via two adjacent modified bases.
39. The molecular junction sensor of claim 36, wherein the molecular wire comprises a multi-stranded nucleic acid comprising a first strand and a second strand and wherein the universal receptor is conjugated to the molecular wire via at least a first anchor point located on the first strand and at least a second anchor point located on the second strand.
40. The molecular junction sensor of any one of claims 17-39, wherein the sensor comprises an array of sensing channels and at least one reference channel lacking a receptor or analyte-binding moiety.
41. The molecular junction sensor of any one of claims 17-40, wherein output from the at least one reference channel is used to normalize drift associated with pH, ionic strength, matrix composition, biofouling, lifetime effects, or device-to-device variation.Atorney Docket No. 22824.002WO-PCT42. The molecular junction sensor of any one of claims 17-41, wherein transient binding events are characterized by one or more features selected from the group consisting of event amplitude, dwell time, and event rate.
43. The molecular junction sensor of any one of claims 17-42, wherein a diagnostic output is generated after accumulation of sufficient event statistics to satisfy a predetermined confidence threshold or time-to-result criterion.
44. The molecular junction sensor of any one of claims 17-43, wherein analyte identification or concentration estimation is performed using a trained classifier or a trained regression model.
45. The molecular junction sensor of claim 44, wherein the trained classifier or trained regression model comprises one or more of a support vector machine, a kernel classifier, a linear classifier, a tree-based model, a hyperdimensional model, a ridge regression model, or a combination thereof.
46. The molecular junction sensor of any one of claims 17-45, wherein the molecular junction sensor is configured for time-resolved, event-based detection of analyte binding events.
47. The molecular junction sensor of any one of claims 17-46, wherein the sensor comprises a plurality of sensing channels, a first sensing channel comprising a calixarene-based universal receptor and a second sensing channel comprising a cyclodextrin-based universal receptor.
48. The molecular junction sensor of any one of claims 17-47, wherein the sensor comprises a plurality of sensing channels comprising calixarene-based hosts, cyclodextrin-based hosts, or a combination thereof.
49. A method of detecting and quantifying metabolites, drugs, hormones, sugars, amino acids, and / or neurotransmitters, comprising:Atorney Docket No. 22824.002WO-PCTcontacting a biofluid sample with a universal receptor or a molecular junction sensor, wherein the universal receptor comprises a macrocyclic host configured to bind small molecules through noncovalent interactions and is functionalized for conjugation to a molecular wire, andwherein the molecular junction sensor comprises the universal receptor, a molecular wire conjugated to the universal receptor to form a molecular junction with nanostructures or nanoparticles, and a pair of electrodes, the molecular junction being configured to bridge the pair of electrodes and to transduce binding-induced conformational changes into measurable electrical signals.
50. The method of claim 49, wherein the biofluid sample is selected from the group consisting of sweat, saliva, urine, blood, interstitial fluid, an artificial sweat composition, and an interstitial-fluid-like matrix.
51. The method of claim 49 or 50, wherein the method detects and quantifies at least one molecule selected from the group consisting of glucose, lactate, hydroxybutyrate, uric acid, creatinine, urea, cortisol, dopamine, and serotonin.
52. The method of claim 51, wherein the method detects and quantifies any combination of glucose, lactate, hydroxybutyrate, uric acid, creatinine, and urea.
53. The method of claim 51, wherein the method detects and quantifies any combination of glucose, P-hydroxybutyrate, cortisol, lactate, uric acid, creatinine, urea, dopamine, and serotonin.
